LONDON--(BUSINESS WIRE)--Technavio has announced the top six leading vendors in their recent global generic drugs market report. This research report also lists 49 other prominent vendors that are expected to impact the market during the forecast period.
Competitive vendor landscape
According to Technavio researchers, the global generic drugs market is fragmented with the top vendors accounting for about 26% of the global generic sales. These vendors continually compete for the top position, with occasional spurts of competition coming from local manufacturers. The market is characterized by the presence of a large number of local, large pharmaceutical companies, and is densely distributed with suppliers. The top international pharmaceutical companies are facing challenges in the form of price pressure, regulatory constraints, and competition from local and international pharmaceutical companies.
Imran Mushtaq, a lead analyst at Technavio for research on cardiovascular and metabolic disorders, says, “Following the increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions, the competition in the market is expected to intensify. Top pharmaceutical companies adopting these strategies can grow significantly during the forecast period and increase their revenue.”
Request for sample report: http://goo.gl/J04Nw8
Top six generic drugs market vendors
Teva Pharmaceuticals, incorporated in 1944, is headquartered in Petah Tikva, Israel. The company sells generics and specialty pharmaceuticals worldwide. It has operations in 60 countries, and its products are sold in over 100 countries.
The company has an established presence in the global generic drugs market, with key products such as Copaxone, Azilect, Plan B One-Step, ParaGard T 380 A, Actiq, and Amrix.
Sandoz, founded in 1886, is headquartered in Holzkirchen, Germany. The company provides generics spanning oral solids, gels and patches, injectables, and biosimilars. It operates as a generic pharmaceuticals division of Novartis.
Sandoz is a leading supplier of generics, with a product portfolio of over 1,000 different medicines. In 2014, the company launched 28 new products in the US. In ROW, it launched three new products in Japan — valsartan, a generic version of Novartis’ Diovan tablets, zoledronic acid, and Losarhyd, a generic version of MSD’s tablets LD. It also launched a generic version of Novartis’ Zometa for intravenous infusion in the region. It expanded its TB portfolio in Africa and is among the primary suppliers of TB medicines to the WHO.
Allergan, formerly Actavis, was incorporated in 2013 and is headquartered in Dublin, Ireland. The company develops and commercializes pharmaceuticals, medical devices, biologics, and OTC products in the US, Central and South America, Europe, and APAC. It focuses on therapeutic areas, including ophthalmology, neurology, urology, and dermatology.
Allergan has an established presence in the generic drugs market with 250 generic product families, including Lo Loestrin Fe, Amethia, Bupropion hydrochloride ER, Celecoxib, Desonide lotion and cream, Lidocaine topical patch, and Methylphenidate.
Mylan, established in 1961, is headquartered in Pennsylvania, US. The company develops, manufactures, licenses, and markets generic and specialty pharmaceutical products in the dermatology and cardiovascular therapeutic areas.
Mylan ranks number one in the US generics prescription market in terms of sales and number two in terms of prescriptions dispensed. It sells around 360 generic products in the US.
Sun Pharmaceuticals, founded in 1983, is headquartered in Mumbai, India. The company has a portfolio that includes drugs in the therapy areas of cardiology, diabetes, neurology, psychiatry, and gastroenterology. In FY2014, the company reported revenue of USD 4.5 billion.
Sun Pharmaceuticals has an established presence in the generic drugs market. It is the fifth largest pharmaceutical company in the US.
STADA Arzneimittel, founded in 1895, is headquartered in Bad Vilbel, Germany. The company manufactures generics and branded products such as Grippostad, Ladival, Covonia, and Aqualor. In FY2014, the company reported revenue of USD 2.74 billion.
STADA Arzneimittel’s top-selling generic drugs:
|Drugs||Revenue 2014 (USD millions)|
Browse Related Reports:
- Global Human Vaccine Market 2016-2020
- Global Antibody Drug Conjugates Market 2016-2020
- Global Immunotherapy Drugs Market 2016-2020
Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact email@example.com with your requirements and a link to our subscription platform.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.